Literature DB >> 7802486

The characterization of Leishmania parasites and their vectors from Central America using molecular techniques.

R Zeledón1, R Maingon, R Ward, B Arana, A Belli, P de Carreira, C Ponce.   

Abstract

The disfiguring cutaneous and mucocutaneous and often fatal visceral forms of leishmaniasis are an increasing public health problem in Central America. There are some evidences of a highest prevalence of L. braziliensis and L. mexicana in Guatemala; L. braziliensis, L. panamensis and L. infantum (L. chagasi) in Honduras and Nicaragua, and L. panamensis in Costa Rica and Panamá. Our research project, just starting, attempts to use molecular approaches for a more rapid and accurate diagnosis and to identify the parasites. The techniques include non-radioactive DNA probes, PCR, schizodeme, isoenzyme analysis and monoclonal antibodies; and specific recombinant peptides will be used to improve immunodiagnosis of the visceral form. Intra-specific heterogeneity in Leishmania isolates will be examined by pulsed field electrophoresis and random amplified polymorphic DNA. Using selected strains, the techniques will be compared on a regional basis leading to a better knowledge of parasite distribution and the related clinical entities. Furthermore, DNA probes for the identification of parasites in vectors and for sibling species of vectors, are also to be applied; chemical identification of sandfly male pheromones will be attempted possibly leading to potential novel control measures.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7802486

Source DB:  PubMed          Journal:  Arch Inst Pasteur Tunis        ISSN: 0020-2509


  1 in total

1.  Detection and identification of Leishmania spp.: application of two hsp70-based PCR-RFLP protocols to clinical samples from the New World.

Authors:  Ana M Montalvo; Jorge Fraga; Dídier Tirado; Gustavo Blandón; Annia Alba; Gert Van der Auwera; Iván Darío Vélez; Carlos Muskus
Journal:  Parasitol Res       Date:  2017-06-01       Impact factor: 2.289

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.